Neurotech Board Changes

Lincoln and Paris, March 14, 2005 – Neurotech announced today that Bernard Chauvin has resigned as Non-Executive Chairman in order that Neurotech can appoint a Chairman with a North American presence.

Neurotech has made significant progress over the past two years and has evolved from its French origin into a predominantly US business. Based out of Lincoln, Rhode Island, the team continues to benefit from the leadership of Bernard Davitian as President, as well as Weng Tao – Chief Scientific Officer and Vice President of Research & Development, Bill Tente –Vice President of Manufacturing, and the recently appointed Al Reaves – Vice President of Clinical Development.

Neurotech is currently seeking an experienced US-based Chief Executive Officer as well as a Non-Executive Chairman who will take the company forward in its next step of development.

Elkan Gamzu, who is a Non-Executive Director, has taken up the post of interim Chairman until such time as a Chairman is appointed. Elkan is based in the greater Boston area and as such is better placed geographically to support Neurotech’s US operations.

About Neurotech
Neurotech is a biotechnology company specialized in the development of innovative technologies for the treatment of retinal diseases. The Company is headquartered in Paris with an American subsidiary, Neurotech USA, Inc., located in Lincoln, RI, south of Boston. Neurotech is supported in its scientific and business strategies by world experts in ophthalmology and by a group of international investors led by Apax Partners and Merlin Biosciences.

To learn more about Neurotech, please visit our web site at www.neurotechusa.com